Plitidepsin

Chemical compound From Wikipedia, the free encyclopedia

Plitidepsin, also known as dehydrodidemnin B and sold under the brand name Aplidin, is a chemical compound extracted from the ascidian Aplidium albicans.[3]

Quick facts Names, Identifiers ...
Plitidepsin
Names
Systematic IUPAC name
(2S)-N-[(1R)-1-({(3S,6R,7S,10R,11S,15S,17S,20S,25aS)-10-[(2S)-Butan-2-yl]-11-hydroxy-3-[(4-methoxyphenyl)methyl]-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,8,13,16,18,21-heptaoxo-15-(propan-2-yl)docosahydro-15H-pyrrolo[2,1-d][10,19,1,4,7,14]dioxatetraazacyclotricosin-7-yl}carbamoyl)-3-methylbutyl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
Other names
Aplidine; Aplidin, dehydrodidemnin B; Aplidin; N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
KEGG
UNII
  • InChI=1S/C59H91N7O14/c1-15-35(8)50-47(69)30-49(71)80-53(34(6)7)52(72)37(10)54(73)60-41(26-32(2)3)58(77)65-24-16-18-42(65)48(70)31-63(12)44(29-39-20-22-40(79-14)23-21-39)46(68)28-36(9)51(56(75)61-50)62-55(74)45(27-33(4)5)64(13)59(78)43-19-17-25-66(43)57(76)38(11)67/h20-23,32-37,41-45,47,50-51,53,69H,15-19,24-31H2,1-14H3,(H,60,73)(H,61,75)(H,62,74)/t35-,36-,37-,41-,42-,43-,44-,45+,47-,50+,51-,53-/m0/s1
    Key: RZFJKZZAZSUBCF-VETSTYKFSA-N
  • O=C([C@@H](NC([C@@H](C)C([C@@H](OC(C[C@H](O)[C@H](NC([C@@H](NC([C@H](N(C([C@H]1N(C(C(C)=O)=O)CCC1)=O)C)CC(C)C)=O)[C@@H](C)OC([C@H](CC2=CC=C(OC)C=C2)N3C)=O)=O)[C@@H](C)CC)=O)C(C)C)=O)=O)CC(C)C)N4[C@H](C3=O)CCC4
Properties
C57H87N7O15
Molar mass 1110.357 g·mol−1
Pharmacology
L01XX57 (WHO)
Legal status
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkYX markN ?)
Close

Medical uses

In Australia, plitidepsin, in combination with dexamethasone, is indicated for the treatment of people with relapsed and refractory multiple myeloma.[1][2][4]

Pharmacological activity

Plitidepsin exhibits antitumor, antiviral and immunosuppressive activities. It shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.[5][6]

Plitidepsin inhibits the human protein eEF1A which has potential interactions with multiple coronavirus proteins. Plitidepsin possesses antiviral activity against SARS-CoV-2 in vitro and in an in vivo mouse model.[7]

Society and culture

In July 2003, plitidepsin was granted orphan drug status by the European Medicines Agency (EMA) for treating acute lymphoblastic leukemia.[8] In December 2017, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorization for the treatment of multiple myeloma.[9] After a re-examination of the opinion, the refusal of the marketing authorization was confirmed in March 2018.[9] The CHMP is of the opinion that the benefits of Aplidin do not outweigh its risks.[9] In October 2020, the General Court upheld PharmaMar's appeal and annulled the decision refusing marketing authorization for Aplidin, and the European Commission then returned the application for Aplidin to the EMA.[9][10] In July 2025, PharmaMar withdrew its application for a marketing authorization of Aplidin for the treatment of multiple myeloma.[9]

Plitidepsin was approved for medical used in Australia in December 2018.[2]

References

Further reading

Related Articles

Wikiwand AI